Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 35.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,875 shares of the medical research company’s stock after purchasing an additional 1,005 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Thermo Fisher Scientific were worth $2,057,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Halpern Financial Inc. raised its position in Thermo Fisher Scientific by 307.7% during the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 40 shares in the last quarter. Coppell Advisory Solutions LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at approximately $33,000. Live Oak Investment Partners purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $36,000. Tyler Stone Wealth Management purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $37,000. Finally, Indiana Trust & Investment Management CO purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $569.22 on Wednesday. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The business’s fifty day simple moving average is $563.78 and its 200-day simple moving average is $519.45. The firm has a market cap of $217.05 billion, a PE ratio of 36.84, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. During the same quarter in the prior year, the company earned $5.40 EPS. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. HSBC assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They issued a “buy” rating and a $610.00 price objective for the company. TheStreet upgraded Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Robert W. Baird reiterated an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price target for the company. Finally, Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $599.00.

Check Out Our Latest Analysis on TMO

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.